Fosun Sells China Rights for Diabetes Drug to Salubris

Fosun Pharma out-licensed China rights for a diabetes drug, a DPP4 inhibitor known as fotagliptin benzoate, to Shenzhen Salubris for 25 million RMB ($4.1 million). Earlier this week, Sellas Pharma of Greece bought global rights to the drug – with the exception of China – for $269 million (the deal included rights to cancer drug, a pan-HER inhibitor, which took the total value of the transaction up to $536 million). More details.... Stock Symbols: (SHA: 600196; HK: 02196) (SHE: 002294) Share this with colleagues: // //